- Home
- STEC vs BLRX Comparison
STEC vs BLRX Comparison
Compare STEC & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- BLRX
- Stock Information
- Founded
- STEC 2006
- BLRX 2003
- Country
- STEC China
- BLRX Israel
- Employees
- STEC N/A
- BLRX N/A
- Industry
- STEC
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- BLRX Health Care
- Exchange
- STEC NYSE
- BLRX Nasdaq
- Market Cap
- STEC 31.4M
- BLRX 36.0M
- IPO Year
- STEC 2021
- BLRX 2011
- Fundamental
- Price
- STEC $0.73
- BLRX $0.20
- Analyst Decision
- STEC
- BLRX Strong Buy
- Analyst Count
- STEC 0
- BLRX 2
- Target Price
- STEC N/A
- BLRX $5.50
- AVG Volume (30 Days)
- STEC 288.3K
- BLRX 2.2M
- Earning Date
- STEC 12-31-2024
- BLRX 11-25-2024
- Dividend Yield
- STEC N/A
- BLRX N/A
- EPS Growth
- STEC N/A
- BLRX N/A
- EPS
- STEC N/A
- BLRX N/A
- Revenue
- STEC $260,474,693.00
- BLRX $21,991,000.00
- Revenue This Year
- STEC $9.76
- BLRX N/A
- Revenue Next Year
- STEC $15.85
- BLRX N/A
- P/E Ratio
- STEC N/A
- BLRX N/A
- Revenue Growth
- STEC N/A
- BLRX N/A
- 52 Week Low
- STEC $0.20
- BLRX $0.19
- 52 Week High
- STEC $3.25
- BLRX $1.70
- Technical
- Relative Strength Index (RSI)
- STEC 41.44
- BLRX 24.20
- Support Level
- STEC $0.72
- BLRX $0.23
- Resistance Level
- STEC $0.84
- BLRX $0.56
- Average True Range (ATR)
- STEC 0.11
- BLRX 0.03
- MACD
- STEC -0.01
- BLRX -0.00
- Stochastic Oscillator
- STEC 29.76
- BLRX 7.26
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.